One of our initial concerns about Lu-PSMA therapy was xerostomia, which could arise given the physiological uptake of this tracer by the salivary glands; however, the side effects up to 2 months after the second cycle were mild and transient and occurred in just 8.7% of patients; in all cases the symptoms were tolerable and patients only mentioned it after they were asked directly about this side effect. The gene discussed is FOLH1; the disease is xerostomia.